Boston Scientific stock sinks toward 52-week lows as medtech selloff deepens
Published on 08/25/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific (US10117L1017) stock traded at $48.92 on August 25, 2026 at 1:49 p.m. ET, down 2.89% on the day as the selloff in medical device names continues to pressure the shares. Intraday market data show the stock changing hands on the NYSE in the high-$40 range, leaving the company well below its recent highs.
Steep drawdown despite growth profile
The pressure on Boston Scientific stock stands out given the company’s fundamental profile highlighted in a recent sector overview. The analysis describes Boston Scientific as a diversified medtech leader with a market capitalization of $73 billion based on current trading levels. In that same overview, Boston Scientific is cited as growing revenue at a 13.5% rate with a return on equity of 15.5%, metrics that underscore the underlying momentum in the business.
Yet the shares have moved sharply lower in 2026. According to the intraday quote page, Boston Scientific’s year-to-date total return stood at -48.72% as of August 25, 2026, while the S&P 500 index showed a gain of 11.76% over the same span. That comparison highlights how the stock has lagged the broader U.S. equity benchmark by more than 60 percentage points this year despite its growth metrics.
Valuation reset and analyst targets
The same medtech sector piece characterizes Boston Scientific as a “fallen angel,” arguing that the valuation reset has been significant. Based on that discussion, the shares are trading at 15 times forward earnings, a multiple that the commentary frames as inexpensive for a company delivering revenue growth in the mid-teens and double-digit returns on equity. The authors add that a 47% year-to-date decline and a 55% drawdown from previous highs have created what they describe as a notable entry point for long-term medtech investors, and they note that the consensus analyst price target implies 21.6% upside from recent levels.
Separate filings-driven coverage of institutional positioning adds another angle to the story. One recent report on institutional holdings notes that a bank purchased a new stake in Boston Scientific, with the article citing a share price of $48.98 in the August 25, 2026 session. This snapshot aligns with the broader price data and reinforces that institutional investors are still engaging with the name even after the sharp drawdown.
Shareholder base and consensus view
The same holdings coverage also summarizes the current consensus stance on Boston Scientific. In that overview, the stock is assigned a consensus rating of “Moderate Buy,” with a consensus target price of $71.62 among covering analysts. The report indicates that, despite the recent volatility, the analyst community still expects meaningful upside from current trading levels on a 12-month view.
Viewed together, these data points suggest that Boston Scientific’s steep share-price decline in 2026 reflects sector-wide risk repricing and sentiment rather than a collapse in company-specific fundamentals. The combination of double-digit revenue growth, mid-teens return on equity, and a valuation multiple in the mid-teens on forward earnings stands in contrast to the stock’s nearly 49% negative year-to-date performance and 55% fall from its highs, as highlighted in the medtech sector commentary.
Cardiovascular portfolio remains central
Beyond the market moves, Boston Scientific’s operating story is anchored in its cardiovascular and minimally invasive device portfolio. The company’s product lineup includes stents, catheters, ablation systems, and implantable devices used to treat conditions ranging from coronary artery disease to structural heart problems and cardiac rhythm disorders. This diversification across high-need therapeutic areas helps support the revenue growth profile cited in the sector review, with multiple product families contributing to mid-teens top-line expansion.
In interventional cardiology, Boston Scientific has built out families of drug-eluting stents and related delivery systems designed to keep coronary arteries open after angioplasty procedures. In cardiac rhythm management, it offers pacemakers, defibrillators, and related leads intended to help maintain stable heart rhythms. Additionally, the company has expanded into structural heart interventions, such as devices aimed at left atrial appendage closure for patients with atrial fibrillation who are at elevated stroke risk. These platforms give Boston Scientific exposure to aging populations and chronic disease trends that typically support steady procedure volumes over time.
Stock level and investor takeaway
From a trading perspective, Boston Scientific stock remains well below the consensus fair-value estimates cited in recent coverage. With the shares at $48.92 as of 1:49 p.m. ET on August 25, 2026 and the consensus target at $71.62, the implied upside is more than 45% relative to that intraday quote if the target were to be reached. At the same time, the shares’ -48.72% year-to-date return compared to an 11.76% gain for the S&P 500 illustrates how sentiment has shifted against the name in 2026, even as revenue growth of 13.5% and a 15.5% return on equity position the company in the upper tier of large-cap medtech peers.
For investors, the central question is whether the current valuation reset, including the 55% drawdown from prior highs cited in the sector piece, has already priced in the macro and sector headwinds or whether further downside is possible if procedure volumes or capital spending soften. The data points available as of late August 2026 show a company with a diversified cardiovascular device portfolio, solid profitability metrics, and analyst expectations of double-digit growth, trading at a forward multiple and absolute price level that reflect significant multiple compression compared with the past few years.
Read more
More on Boston Scientific stock
Minimally invasive heart therapies
One representative area of Boston Scientific’s portfolio is its minimally invasive therapies for structural heart conditions. The company has developed transcatheter devices intended to reduce stroke risk in patients with atrial fibrillation, as well as technologies that support left atrial appendage closure procedures. These offerings are designed to be delivered via catheter rather than open-heart surgery, which can shorten recovery times and expand treatment eligibility for patients who might not tolerate more invasive procedures. As demand for atrial fibrillation interventions grows globally, this franchise is positioned to contribute further to the revenue growth rates highlighted in recent medtech sector analyses.
Boston Scientific stock at late August 2026 levels
Boston Scientific stock traded at $49.01 at the close of regular NYSE trading on August 24, 2026, down 2.70% for that session before a modest overnight move on an alternative trading system. The latest quote overview shows the shares at $49.00 in overnight trading at 2:33 a.m. ET on August 25, 2026, setting the stage for the subsequent intraday decline to $48.92 later that day. These levels leave Boston Scientific’s market capitalization at roughly $73 billion on the calculations cited in the medtech sector commentary, underscoring how far the stock has retreated in market value terms during 2026 even as the underlying business continues to post double-digit revenue growth.
Fact box
Company: Boston Scientific Corp.
ISIN: US10117L1017
Ticker: BSX
Exchange: NYSE
Price (as of August 25, 2026, 1:49 p.m. ET): $48.92 USD
